



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | | | |
|---|---|--|---|---|
| (51) International Patent Classification ⁶ : A61F 2/04, 2/06 | A1 | (11) International Publication Number: WO 00/32136 (43) International Publication Date: 8 June 2000 (08.06.00) | | |
| <table style="width: 100%; border: none;"> <tr> <td style="width: 50%; vertical-align: top; padding: 5px;"> (21) International Application Number: PCT/IL99/00648 (22) International Filing Date: 1 December 1999 (01.12.99) (30) Priority Data: 09/204,830 3 December 1998 (03.12.98) US (71) Applicant (for all designated States except US): MEDINOL LTD. [IL/IL]; Building 3, Kiryat Atidim, 61581 Tel Aviv (IL). (72) Inventor; and (75) Inventor/Applicant (for US only): RICHTER, Jacob [IL/IL]; Anafa Street 8, 47266 Ramat Hsharon (IL). (74) Agent: EITAN, PEARL, LATZER & COHEN-ZEDEK; 2 Gav Yam Center, Shenkar Street 7, 46725 Herzlia (IL). </td> <td style="width: 50%; vertical-align: top; padding: 5px;"> (81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> </td> </tr> </table> | | | (21) International Application Number: PCT/IL99/00648 (22) International Filing Date: 1 December 1999 (01.12.99) (30) Priority Data: 09/204,830 3 December 1998 (03.12.98) US (71) Applicant (for all designated States except US): MEDINOL LTD. [IL/IL]; Building 3, Kiryat Atidim, 61581 Tel Aviv (IL). (72) Inventor; and (75) Inventor/Applicant (for US only): RICHTER, Jacob [IL/IL]; Anafa Street 8, 47266 Ramat Hsharon (IL). (74) Agent: EITAN, PEARL, LATZER & COHEN-ZEDEK; 2 Gav Yam Center, Shenkar Street 7, 46725 Herzlia (IL). | (81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> |
| (21) International Application Number: PCT/IL99/00648 (22) International Filing Date: 1 December 1999 (01.12.99) (30) Priority Data: 09/204,830 3 December 1998 (03.12.98) US (71) Applicant (for all designated States except US): MEDINOL LTD. [IL/IL]; Building 3, Kiryat Atidim, 61581 Tel Aviv (IL). (72) Inventor; and (75) Inventor/Applicant (for US only): RICHTER, Jacob [IL/IL]; Anafa Street 8, 47266 Ramat Hsharon (IL). (74) Agent: EITAN, PEARL, LATZER & COHEN-ZEDEK; 2 Gav Yam Center, Shenkar Street 7, 46725 Herzlia (IL). | (81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> | | | |
| (54) Title: CONTROLLED DETACHMENT STENTS | | | | |
| | | | | |
| (57) Abstract <p>A stent (1) is provided with specific "designated detachment" points or zones (3), such that after the stent is deployed, the stress applied on the stent will cause the stent to detach at these designated detachment points or zones. When the detachment occurs completely around the circumference of the stent, the stent separates into stent segments (2) each able to move with the vessel independently of the other stent segments. The components (4) at the designated detachment zones may have a cross-sectional area sufficiently low so that the components will detach under the stress placed on the stent after implantation. Alternatively or additionally, the components at the designated detachment zones may be made of a material that is sufficiently weaker so that the components will detach under the stress placed on the stent after implantation. The stent may have a lower number of components at the designated detachment zones than in the stent segments.</p> | | | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|-----------|--------------------------|-----------|--|-----------|--|-----------|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | | | TR | Turkey |
| BG | Bulgaria | HU | Hungary | ML | Mali | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MN | Mongolia | UA | Ukraine |
| BR | Brazil | IL | Israel | MR | Mauritania | UG | Uganda |
| BY | Belarus | IS | Iceland | MW | Malawi | US | United States of America |
| CA | Canada | IT | Italy | MX | Mexico | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NE | Niger | VN | Viet Nam |
| CG | Congo | KE | Kenya | NL | Netherlands | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NO | Norway | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's Republic of Korea | NZ | New Zealand | | |
| CM | Cameroon | KR | Republic of Korea | PL | Poland | | |
| CN | China | KZ | Kazakhstan | PT | Portugal | | |
| CU | Cuba | LC | Saint Lucia | RO | Romania | | |
| CZ | Czech Republic | LI | Liechtenstein | RU | Russian Federation | | |
| DE | Germany | LK | Sri Lanka | SD | Sudan | | |
| DK | Denmark | LR | Liberia | SE | Sweden | | |
| EE | Estonia | | | SG | Singapore | | |

CONTROLLED DETACHMENT STENTS

FIELD OF THE INVENTION

The invention relates generally to stents, which are endoprotheses implanted into vessels within the body, such as a blood vessels, to support and hold open the
5 vessels, or to secure and support other endoprotheses in vessels.

BACKGROUND OF THE INVENTION

Various stents are known in the art. Typically stents are generally tubular in shape, and are expandable
10 from a relatively small, unexpanded diameter to a larger, expanded diameter. For implantation, the stent is typically mounted on the end of a catheter, with the stent being held on the catheter at its relatively small, unexpanded diameter. By the catheter, the unexpanded stent is directed
15 through the lumen to the intended implantation site. Once the stent is at the intended implantation site, it is expanded, typically either by an internal force, for example by inflating a balloon on the inside of the stent, or by allowing the stent to self-expand, for example by removing a
20 sleeve from around a self-expanding stent, allowing the stent to expand outwardly. In either case, the expanded stent resists the tendency of the vessel to narrow, thereby maintaining the vessel's patency.

Some examples of patents relating to stents
25 include U.S. Patent No. 4,733,665 to Palmaz; U.S. Patent No.

4,800,882 and 5,282,824 to Gianturco; U.S. Patent Nos.
4,856,516 and 5,116,365 to Hillstead; U.S. Patent Nos.
4,886,062 and 4,969,458 to Wiktor; U.S. Patent No. 5,019,090
to Pinchuk; U.S. Patent No. 5,102,417 to Palmaz and Schatz;
5 U.S. Patent No. 5,104,404 to Wolff; U.S. Patent No.
5,161,547 to Tower; U.S. Patent No. 5,383,892 to Cardon et
al.; U.S. Patent No. 5,449,373 to Pinchasik et al.; and U.S.
Patent No. 5,733,303 to Israel et al.

One object of prior stent designs has been to
10 insure that the stent has sufficient radial strength when it
is expanded so that it can sufficiently support the lumen.
Stents with high radial strength, however, tend also to have
a higher longitudinal rigidity than the vessel in which it
is implanted. When the stent has a higher longitudinal
15 rigidity than the vessel in which it is implanted, increased
trauma to the vessel may occur at the ends of the stent, due
to stress concentrations on account of the mismatch in
compliance between the stented and un-stented sections of
the vessel.

20

SUMMARY OF THE INVENTION

An object of the invention is to provide a stent
that more closely matches the compliance of the vessel in
which it is implanted, with relatively little or no
sacrifice in radial strength, even when the stent is made
25 very long.

In accordance with one embodiment of the invention, a stent is provided with specific "designated detachment" points, such that after the stent is deployed, and during the motion of the vessel, the stress applied on the stent will cause the stent to segment at these designated detachment points. When the designated detachment points are arranged completely around the circumference of the stent, creating a circumferential "designated detachment" zone, the detachment at the designated detachment points separates the stent into two or more separate stent segments, each able to move with the vessel independently of the other stent segments. Because each stent segment can move with the vessel independently of the other stent segments, the series of stent segments achieves greater compliance between the stented and unstented sections of the vessel than the longer, unitary stent, and it thereby reduces stress on the vessel wall.

The stent is preferably designed such that after detachment, the ends of the stent segments created by the detachment are relatively smooth, so that they do not injure the vessel wall. Also, the stent is preferably configured such that the individual stent segments have sufficient radial strength after detachment, such that the detachment results in little or no significant reduction in the stent's resistance to compression.

The stent may be designed such that detachment occurs only after a period of time after implantation, so that the stent will already be buried under neointima at the time of detachment. Thus, the stent segments remaining
5 after detachment will be held in place by the neointima and will not move relative to the lumen, i.e., they will not "telescope" into one another, and they will not move away from one another, creating unsupported gaps.

A variety of mechanisms may be used to accomplish
10 the detachment. For example, the stent may be provided at certain points or zones along its length with components having a cross-sectional area sufficiently low so that the stent segments will detach preferentially under the stress placed on the stent after implantation. Alternatively or
15 additionally, the stent may be provided at certain points or zones along its length with components made of a material that is sufficiently weaker than elsewhere in the stent so that the stent segments will detach preferentially under the stress placed on the stent after implantation.

20 Alternatively or additionally, the stent may be designed such that it has a lower number of components, or struts, at the designated detachment zones, so that each such component bears more load than components elsewhere in the stent. These components are configured to separate under the
25 increased loads they bear when the stent is repeatedly stressed after implantation.

The factors contributing to detachment may be applied individually or in combination. For example, the designated detachment struts may have low cross-sectional areas and also may be formed of weaker material, or the
5 designated detachment zones may have a reduced number of components, with or without the components having low cross-sectional areas and/or being formed of weaker material.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows a schematic diagram of a stent, generally in
10 the form of a cylinder, having designated detachment zones between stent segments;

Figure 2 shows a schematic diagram of the stent of Figure 1 after detachment, in which the stent has separated into a series of shorter stent segments;

15 Figure 3 shows a flat layout of a stent pattern in which the components in the designated detachment zones have a cross-sectional area that is sufficiently low so that the stent segments will detach under the stress placed on the stent after implantation;

20 Figure 4 shows a flat layout of the stent pattern of Figure 3, after detachment has occurred at the designated detachment zones; and

Figure 5 shows a flat layout of a stent pattern in which the stent has a lower number of components at the
25 designated detachment zones, so that each such

component bears an increased load and separates under such increased load.

DETAILED DESCRIPTION OF THE DRAWINGS

Figure 1 shows a schematic diagram of a stent 1, generally in the form of a cylinder. The stent 1 comprises a series of stent segments 2 separated by designated detachment zones 3. The designated detachment zones 3 comprise one or more designated detachment components or struts (see Figures 3 through 5).

The designated detachment zones 3 are designed such that the designated detachment components or struts separate under repeated stress placed on the stent 1 after implantation. When all of the designated detachment struts around the circumference of the stent in a particular designated detachment zone 3 separate, the stent is itself separated into a series of independent stent segments 2, as shown in Figure 2. The designated detachment zones 3 may be designed such that detachment does not occur until some time has passed after implantation, so that the stent segments 2 will already be buried under neointima at the time of detachment and therefore will not move relative to the lumen.

Persons of ordinary skill in the art will appreciate that the basic geometry of the stent segments 2 may take any suitable form, and that the stent segments 2

may be formed of any suitable material. Examples of suitable structures for the stent segments 2 include those shown in U.S. Patent No. 5,733,303 to Israel et al., the disclosure of which is hereby expressly incorporated by
5 reference into this application.

Figure 3 shows a flat layout of a stent pattern comprising stent segments 2 separated by designated detachment zones 3. In the finished stent, each stent segment 2 in this embodiment has a configuration generally
10 corresponding to a stent configuration disclosed in U.S. Patent No. 5,733,303. The stent segments 2 are joined to each other by the designated detachment components or struts 4 in the designated detachment zones 3.

In this embodiment, each of the designated
15 detachment struts 4 has a reduced cross-sectional area that is sufficiently low to allow separation of the designated detachment struts 4 under the stress placed on the stent after implantation. The amount of reduction of the cross-section of the detachment struts 4 as compared to, for
20 example, the components labeled by reference numeral 5 in the stent segments 2, may be, for example, on the order of tens of percents. For example, the detachment struts 4 may be 25% to 75% thinner or narrower than the components 5.

These designated detachment struts 4 may
25 additionally or alternatively be made of a weaker material, in order to insure appropriate separation. The weaker

material may be provided either in the stock material used to form the designated detachment struts 4, or by treating the designated detachment struts 4 (or the designated detachment zones 3) after the stent has been produced, such
5 that the treatment weakens the material of the designated detachment struts 4.

One example of a manner of providing the designated detachment struts with weaker material is to form the entire stent of NiTi and then to treat the designated
10 detachment struts to be Martensitic while the remaining components will be in the Austenitic phase. Another example, for example in a stent made of SST, is to anneal the components in the designated detachment zones and harden the components in the stent segments.

15 In addition to the reduction in cross-section, the remaining geometry of the designated detachment struts may be selected to achieve the desired results. As shown in Figure 3, the width A of the row of designated detachment struts 4 may be narrower than the width of a corresponding
20 row of components in the stent segment 2, for example the width B of the row of components labeled by reference numeral 5. This reduced width at the designated detachment zones 3 helps to insure detachment at the designated detachment zones 3 under longitudinal repeat bending. Also,
25 the designated detachment struts 4 may be made sufficiently short to reduce the length of the free ends after

separation, so as not to leave long, hanging ends after detachment. For example, the length of the designated detachment struts 4 is shorter than the length of the components 5.

5 Figure 4 shows a flat layout of the stent pattern of Figure 3 after detachment has occurred at the designated detachment zones 3. As shown in Figure 4, the stent after detachment comprises a series of separated and independent stent segments 2. As also seen in Figure 4, because the
10 designated detachment struts 4 were short, the length of the free ends 6 after separation is kept to a minimum.

 Figure 5 shows an alternative design in which, in the designated detachment zones 3, the stent is provided with a lower number of components 7 around the circumference
15 of the stent. In the embodiment shown in Figure 5, each designated detachment zone 3 has five designated detachment struts 7 around the circumference of the stent. By comparison, the stent has nine of the components labeled as component 5 in a band of such components within the stent
20 segments 2. Of course, different numbers of designated detachment struts and stent segment components may be used, without departing from the general concept of the invention.

 The designated detachment struts 7 are configured such that they detach under the loads they bear on account
25 of the stress placed on the stent after implantation. As shown in Figure 5, the designated detachment struts 7 may

also have a reduced cross-sectional area. Also, as with the designated detachment struts in other embodiments, the designated detachment struts 7 may additionally be formed of weaker material, or the designated detachment struts 7 or
5 zones 3 may be treated to make the material weaker after production of the stent.

The embodiments described herein are examples only, as other variations are within the scope of the invention as defined by the appended claims.

What is Claimed is:

1. A stent for implantation in a vessel, wherein the stent comprises:
 - (a) a plurality of stent segments; and
 - 5 (b) means for detachably connecting adjacent stent segments of said plurality of stent segments, said detachable connecting means adapted to permit said adjacent stent segments to separate from each other in response to physiological stress placed
10 on said detachable connecting means, wherein said separation occurs after a period of time after implantation of the stent in the vessel, the period of time being sufficient to permit neointima formation around the stent in an amount
15 sufficient to secure said plurality of stent segments with respect to the vessel.
2. A stent as claimed in claim 1, wherein said detachable connecting means comprises at least one designated detachment strut, wherein the cross-sectional area of
20 the designated detachment strut is sufficiently low so that the designated detachment strut will separate preferentially under stress placed on the stent after implantation.

3. A stent as claimed in claim 1, wherein said detachable connecting means comprises at least one designated detachment strut, wherein the designated detachment strut is made of a material that is sufficiently weaker
5 than elsewhere in the stent so that the designated detachment strut will separate preferentially under stress placed on the stent after implantation.
4. A stent as claimed in claim 1, wherein said detachable connecting means comprises at least one designated
10 detachment strut, wherein the designated detachment strut has a cross-sectional area that is less than the cross-sectional area of a component within one of said stent segments.
5. A stent as claimed in claim 4, wherein the designated
15 detachment strut is also made of a material that is weaker than the material of a component within one of said stent segments.
6. A stent as claimed in claim 1, wherein said detachable connecting means comprises at least one designated
20 detachment strut, wherein the designated detachment strut is made of a material that is weaker than the material of a component within one of said stent segments.

7. A stent as claimed in claim 1, wherein said detachable connecting means comprises at least one designated detachment strut in a designated detachment zone of the stent, wherein the number of designated detachment
5 struts in said designated detachment zone is less than the number of struts that traverse a plane that crosses one of said stent segments perpendicular to an axis of the stent segment.
8. A stent as claimed in claim 7, wherein at least one
10 designated detachment strut has a cross-sectional area that is less than the cross-sectional area of a component within one of said stent segments.
9. A stent as claimed in claim 8, wherein the designated
15 detachment strut is also made of a material that is weaker than the material of a component within one of said stent segments.
10. A stent as claimed in claim 7, wherein at least one
20 designated detachment strut is made of a material that is weaker than the material of a component within one of said stent segments.
11. A stent comprising at least two stent segments and at least one designated detachment strut; and

wherein the designated detachment strut has a cross-sectional area that is less than the cross-sectional area of a component within one of said stent segments.

- 5 12. A stent as claimed in claim 11, wherein the designated detachment strut is also made of a material that is weaker than the material of a component within one of said stent segments.
- 10 13. A stent as claimed in claim 11, wherein the designated detachment strut is in a designated detachment zone of the stent, and wherein the number of designated detachment struts in the designated detachment zone is less than the number of struts that traverse a plane that crosses one of said stent segments perpendicular to an axis of the stent segment.
- 15 14. A stent as claimed in claim 13, wherein the designated detachment strut is also made of a material that is weaker than the material of a component within one of said stent segments.
- 20 15. A stent comprising at least two stent segments and at least one designated detachment strut; and wherein the designated detachment strut is made of

a material that is weaker than the material of a component within one of said stent segments.

16. A stent as claimed in claim 15, wherein the designated detachment strut is in a designated detachment zone of the stent, and wherein the number of designated detachment struts in the designated detachment zone is less than the number of struts that traverse a plane that crosses one of said stent segments perpendicular to an axis of the stent segment.




Fig. 1




Fig. 2




Fig. 3




Fig. 4

3/3




Fig. 5

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IL99/00648**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) :A61F 2/04, 2/06

US CL :623/1.16

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 623/1.16, 1.38

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EAST, WEST

Search Terms: stent, struts, detachable. connectors, breakable, links

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|-----------|---|-----------------------|
| X | US 5,104,404 A (WOLFF) 14 April 1992, col. 3 lines 40-46, Fig. 2. | 1-16 |
| X | US 5,591,197 A (ORTH et al.) 07 January 1997, col. 9 lines 2-4, col. 10 lines 33-47, see Figs. 5A, and 6. | 1-16 |
| X | US 5,807,404 A (RICHTER) 15 September 1998, col. 6 lines 42-67, col. 7 lines 33-36, and Figs. 1, 2 and 7. | 1-16 |



Further documents are listed in the continuation of Box C.



See patent family annex.

| | |
|---|--|
| * Special categories of cited documents: | "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention |
| "A" document defining the general state of the art which is not considered to be of particular relevance | "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone |
| "E" earlier document published on or after the international filing date | "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art |
| "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | "&" document member of the same patent family |
| "O" document referring to an oral disclosure, use, exhibition or other means | |
| "P" document published prior to the international filing date but later than the priority date claimed | |

Date of the actual completion of the international search

11 FEBRUARY 2000

Date of mailing of the international search report

10 MAR 2000

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

BRIAN PELLEGRINO

Telephone No. (703) 306-5899